Snapshot from Jun 28, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Gumokimab
Other

Gumokimab

Tracked across 1 events · 7 articles · First seen Jun 12, 2026 · Last active Jun 12, 2026

Sentiment
75
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
4 75
Business
Akeso's gumokimab approved in China
Akeso announced that the China — National Medical Products Administration of China has approved Gumokimab (AK111), its internally-developed anti-IL-17 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis. The approval was based…
Impact: Gumokimab, an anti-IL-17 monoclonal antibody developed by Akeso, received NMPA approval for moderate-to-severe plaque psoriasis, demonstrating rapid and robust efficacy, durable skin clearance, and a favorable safety profile.
Jun 12, 2026 · 7 articles
Key Actions (3)
100 China — National Medical Products Administration approved GumokimabAkeso's gumokimab approved in China
90 Akeso developed GumokimabAkeso's gumokimab approved in China
60 United States — Center for Drug Evaluation and Research accepted for review GumokimabAkeso's gumokimab approved in China
NEWSDESK
Track Gumokimab live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.